Abstract: Objective To evaluate the efficacy and safety of gemcitabine and cisplatin versus navelbine and cisplatin in anthracycline-and(or)taxane-resistant metastatic breast cancer(MBC).Method A total of 68 patients with metastatic breast cancer were randomly assigned to receive the regimen of GP(n=36)or NP(n=32).Group GP:Gemcitabine 1000mg/m²,d1,d8;DDP 25mg/m²,d1-3.Group NP:Navelbine 25mg/m2,d1,d8;DDP25mg/m²,d1-3.Two groups were treated at least 2 courses with 3 weeks interval,efficacy was evaluated after 2 courses of chemotherapy.Results The response rate was 55.6%(20/36)in group GP,and 53.1%(17/32)in group NP.The degree III-IV thrombocytopenia was more common in group GP than in the group NP,but the degree phlebitis was more serious in group NP.Conclusion NP and GP for treating refractory metastatic breast have a high response rate,there was no significant difference between two groups(χ²=0.0403,P=0.84).Two groups have tolerable side effects.